Victoza, Novo Nordisk’s Type 2 Diabetes Drug, Available in China

Victoza, Novo Nordisks best selling type 2 diabetes drug is now commercially available in China. Victoza, (liraglutide injection), the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analog, was approved for type 2 diabetes by the Chinese State Food and Drug Administration in March 2011… Read more

Novo Nordisk Requests FDA Approval for Ultra-Long-Acting Insulin Degludec

Novo Nordisk filed two new drug applications for the approval of ultra-long-acting insulin degludec and the co-formulation, insulin degludec/insulin aspart (DegludecPlus)
by the U.S. Food and Drug Administration. These new insulin analogs have been developed for the treatment of people with type 1 and type 2 diabetes. Read more

EU Finds Novo Nordisk’s Detemir Safe for Children Aged 2-5

The European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir, in children with type 1 diabetes, aged two to five years. The CHMP decision was made after the review of data demonstrating that insulin detemir… Read more

Victoza: The Earlier The Better, New Study Shows

New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)... Read more

Why Victoza Matters

Why bother adding Victoza to an already lengthy list of treatments for type 2 diabetes? Is marginal improvement in a clinical trial enough to warrant educating physicians and patients about yet another option? Read more

Novo Nordisk New Prefilled Insulin Pen Receives EU Approval

The European Commission has approved Novo Nordisk’s new prefilled insulin pen – FlexTouch for use in the EU. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) – both modern insulins currently delivered in FlexPen.
FlexTouch, the latest prefilled delivery system from Novo Nordisk, offers a new insulin injection experience for users…
Read more

Victoza Found More Effective Than Byetta and Januvia In Treatment of Type 2 Diabetes

New data from two extension studies presented by Novo Nordisk at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) show that Victoza (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies Byetta (exenatide) and Januvia (sitagliptin). Although not.. Read more

Subscribe to our Newsletter

Hide me